

# Alberto Bosi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5022483/publications.pdf>

Version: 2024-02-01

282  
papers

16,535  
citations

15880

67  
h-index

21239

119  
g-index

285  
all docs

285  
docs citations

285  
times ranked

14909  
citing authors

#	ARTICLE	IF	CITATIONS
1	Underestimated Needs for Lymphoma Patients: An Assessment Issue.. Acta Biomedica, 2022, 93, e2022147.	0.2	0
2	One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab. European Journal of Haematology, 2021, 106, 389-397.	1.1	24
3	Non-scarring patchy alopecia: What else, apart from alopecia areata?. Journal of Cutaneous Pathology, 2021, 48, 1282-1285.	0.7	0
4	Serum TARC Concentration Kinetic in Classical Hodgkin Lymphoma during First-Line Treatment. Blood, 2021, 138, 4500-4500.	0.6	1
5	Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML) – a study of 1084 patients. Leukemia, 2020, 34, 1407-1421.	3.3	68
6	Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in acute myeloid leukemia. American Journal of Hematology, 2020, 95, 1304-1313.	2.0	1
7	Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. Journal of Hematology and Oncology, 2020, 13, 115.	6.9	32
8	Multilineage Dysplasia as Assessed by Immunophenotype in Acute Myeloid Leukemia: A Prognostic Tool in a Genetically Undefined Category. Cancers, 2020, 12, 3196.	1.7	4
9	Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial. Blood Advances, 2020, 4, 301-311.	2.5	8
10	Chemotherapy-related nail toxicity. International Journal of Hematology, 2019, 110, 519-520.	0.7	0
11	Influence of Donor and Recipient Gender on Telomere Maintenance after Umbilical Cord Blood Cell Transplantation: A Study by the Gruppo Italiano Trapianto Di Midollo Osseo. Biology of Blood and Marrow Transplantation, 2019, 25, 1387-1394.	2.0	2
12	Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group. Biology of Blood and Marrow Transplantation, 2019, 25, 932-940.	2.0	25
13	One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment. Blood, 2019, 134, 2231-2231.	0.6	5
14	Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.. Journal of Clinical Oncology, 2019, 37, 8040-8040.	0.8	1
15	Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT. Journal of Internal Medicine, 2018, 283, 178-189.	2.7	26
16	“Best practice” for extracorporeal photopheresis in acute and chronic graft-versus-host disease by Societa’ Italiana di Emaferesi and Manipolazione Cellulare and Gruppo Italiano Trapianto Midollo Osseo: a national survey to ascertain its degree of application in Italian transplant centers. Transfusion, 2018, 58, 217-222.	0.8	7
17	Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey. Journal of Blood Medicine, 2018, Volume 10, 21-27.	0.7	2
18	Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica, 2018, 103, 2079-2087.	1.7	225

#	ARTICLE	IF	CITATIONS
19	Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT. <i>American Journal of Hematology</i> , 2018, 93, 1532-1542.	2.0	10
20	The use of Deauville 5-point score could reduce the risk of false-positive fluorodeoxyglucose-positron emission tomography in the posttherapy evaluation of patients with primary bone lymphomas. <i>World Journal of Nuclear Medicine</i> , 2018, 17, 157-165.	0.3	3
21	Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment. <i>Hematological Oncology</i> , 2017, 35, 69-78.	0.8	25
22	Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Bone Marrow Transplantation</i> , 2017, 52, 955-961.	1.3	20
23	Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 22-32.	1.4	7
24	<i>CEBPA</i> "double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features. <i>Haematologica</i> , 2017, 102, 529-540.	1.7	61
25	Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1102-1109.	2.0	9
26	A life-threatening ruxolitinib discontinuation syndrome. <i>American Journal of Hematology</i> , 2017, 92, 833-838.	2.0	38
27	A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach. <i>American Journal of Hematology</i> , 2017, 92, E557-E559.	2.0	10
28	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. <i>Lancet, The</i> , 2017, 390, 555-566.	6.3	444
29	Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. <i>Leukemia</i> , 2017, 31, 2449-2457.	3.3	51
30	Inorganic nanoparticles as potential regulators of immune response in dendritic cells. <i>Nanomedicine</i> , 2017, 12, 1647-1660.	1.7	37
31	Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission. <i>Bone Marrow Transplantation</i> , 2017, 52, 163-166.	1.3	24
32	The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study. <i>Frontiers in Pharmacology</i> , 2017, 8, 413.	1.6	4
33	The <i>hOCT1</i> and <i>ABCB1</i> polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 88021-88033.	0.8	14
34	Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2016, 122, 1880-1887.	2.0	31
35	Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease. <i>Transplantation</i> , 2016, 100, e147-e155.	0.5	40
36	Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. <i>Blood</i> , 2016, 127, 2833-2840.	0.6	207

#	ARTICLE	IF	CITATIONS
37	Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2016, 34, 3627-3637.	0.8	204
38	The circadecadal rhythm of oscillation of umbilical cord blood parameters correlates with geomagnetic activity – An analysis of long-term measurements (1999–2011). <i>Chronobiology International</i> , 2016, 33, 1136-1147.	0.9	8
39	Time related variations in stem cell harvesting of umbilical cord blood. <i>Scientific Reports</i> , 2016, 6, 21404.	1.6	33
40	High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 475-481.	2.0	7
41	New patterns of relapse in multiple myeloma: a case of light chain escape in which FLC predicted relapse earlier than urine and serum immunofixation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 991-5.	1.4	12
42	Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. <i>Oncotarget</i> , 2016, 7, 72311-72321.	0.8	26
43	Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood – a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Hematology and Oncology</i> , 2015, 8, 107.	6.9	35
44	Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biological features and outcome of NPM1-mutated acute myeloid leukemia. <i>Experimental Hematology</i> , 2015, 43, 869-879.e22.	0.2	4
45	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	0.6	72
46	Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAP2000 prospective trial. <i>Bone Marrow Transplantation</i> , 2015, 50, 505-510.	1.3	16
47	FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. <i>Annals of Oncology</i> , 2015, 26, 2155-2161.	0.6	63
48	Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. <i>Leukemia</i> , 2015, 29, 1891-1900.	3.3	199
49	The prognostic value of positron emission tomography performed after two courses (<sc>INTERIM-PET</sc>) of standard therapy on treatment outcome in early stage <sc>H</sc> Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). <i>American Journal of Hematology</i> , 2015, 90, 499-503.	2.0	49
50	Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of 410 years. <i>Bone Marrow Transplantation</i> , 2015, 50, 1508-1512.	1.3	43
51	Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1525-1536.	5.1	143
52	Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide. <i>Leukemia and Lymphoma</i> , 2015, 56, 2388-2391.	0.6	1
53	Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. <i>Transfusion</i> , 2014, 54, 331-339.	0.8	39
54	Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. <i>Leukemia</i> , 2014, 28, 621-628.	3.3	80

#	ARTICLE	IF	CITATIONS
55	Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2071-2078.	0.6	7
56	Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 2014, 55, 781-785.	0.6	8
57	A policy for the disposal of autologous hematopoietic progenitor cells: report from an Italian consensus panel. <i>Transfusion</i> , 2014, 54, 2353-2360.	0.8	12
58	CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia. , 2014, 86, 340-349.		11
59	Romiplostim before splenectomy in a patient with aggressive non-Hodgkin lymphoma and poor response to platelet transfusions. <i>Transfusion Medicine</i> , 2014, 24, 125-126.	0.5	1
60	Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas. <i>European Journal of Haematology</i> , 2014, 93, 129-136.	1.1	25
61	Kinetics of the use of cryopreserved autologous stem cell grafts: a GITMO-SIDEM survey. <i>Cytotherapy</i> , 2014, 16, 101-110.	0.3	6
62	Experts' considerations on HLA haploidentical stem cell transplantation. <i>European Journal of Haematology</i> , 2014, 93, 187-197.	1.1	24
63	Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. <i>Blood</i> , 2014, 123, 1552-1555.	0.6	346
64	The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. <i>Leukemia</i> , 2014, 28, 1804-1810.	3.3	263
65	Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen. <i>Supportive Care in Cancer</i> , 2014, 22, 2557-2561.	1.0	3
66	Skin CD30+ T cells and circulating levels of soluble CD30 are increased in patients with graft versus host disease. <i>Autoimmunity Highlights</i> , 2014, 5, 21-26.	3.9	3
67	Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. <i>Leukemia</i> , 2014, 28, 1811-1818.	3.3	75
68	Primary Prophylaxis of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: Revised Recommendations from a Consensus Process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1080-1088.	2.0	54
69	Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 872-880.	2.0	141
70	Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. <i>Blood</i> , 2014, 123, 2333-2342.	0.6	162
71	Rosiglitazone promotes the differentiation of Langerhans cells and inhibits that of other dendritic cell types from CD133 positive hematopoietic precursors. <i>Histology and Histopathology</i> , 2014, 29, 323-32.	0.5	2
72	A randomized double-blind phase III pivotal study of febuxostat (FEB) versus allopurinol (ALL) in the prevention of tumor lysis syndrome (TLS): Florence study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9641-9641.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013, 88, 581-588.	2.0	61
74	A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. <i>Cytometry Part B - Clinical Cytometry</i> , 2013, 84B, 71-81.	0.7	7
75	Primary lymphoma of bone: outcome and role of surgery. <i>International Orthopaedics</i> , 2013, 37, 2437-2442.	0.9	23
76	Haematopoietic stem cell transplantation: a comparison between the accreditation process performed by competent authorities and JACIE in Italy. <i>Vox Sanguinis</i> , 2013, 105, 174-176.	0.7	3
77	Long-term follow-up of concomitant treatment with romiplostim and warfarin in a patient with immune thrombocytopenia and severe cardiac comorbidities. <i>Platelets</i> , 2013, 24, 242-243.	1.1	2
78	Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1044-1048.	0.6	4
79	Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) survey. <i>Transfusion and Apheresis Science</i> , 2013, 53, 2340-2350.	0.8	59
80	The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: Results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and SocietÀ Italiana di Emaferesi e Manipolazione Cellulare (SidEM) survey. <i>Transfusion and Apheresis Science</i> , 2013, 49, 615-622.	0.5	8
81	Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. <i>Annals of Oncology</i> , 2013, 24, 2430-2434.	0.6	89
82	Allogeneic Hematopoietic Cell Transplantation from Unrelated Donors in Multiple Myeloma: Study from the Italian Bone Marrow Donor Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 940-948.	2.0	20
83	Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis. <i>Haematologica</i> , 2013, 98, e101-e102.	1.7	24
84	Treatment of experimental esophagogastric myotomy with bone marrow mesenchymal stem cells in a rat model. <i>Neurogastroenterology and Motility</i> , 2013, 25, e669-79.	1.6	7
85	The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo. <i>Leukemia</i> , 2013, 27, 2086-2091.	3.3	37
86	Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. <i>Blood</i> , 2013, 121, 5055-5063.	0.6	171
87	Diagnosis of a T-lineage acute lymphoblastic leukemia through digitalized cell analysis of the pleural effusion. <i>International Medical Case Reports Journal</i> , 2013, 6, 77.	0.3	0
88	mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms. <i>PLoS ONE</i> , 2013, 8, e54826.	1.1	80
89	Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor. <i>Blood Transfusion</i> , 2013, 11, 94-101.	0.3	13
90	Evidence for reduced angiogenesis in bone marrow in SSc: immunohistochemistry and multiparametric computerized imaging analysis. <i>Rheumatology</i> , 2012, 51, 1042-1048.	0.9	14

#	ARTICLE	IF	CITATIONS
91	Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. <i>Leukemia</i> , 2012, 26, 1779-1785.	3.3	14
92	Proposed definition of "poor mobilizer"™ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo. <i>Bone Marrow Transplantation</i> , 2012, 47, 342-351.	1.3	156
93	CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease. <i>Haematologica</i> , 2012, 97, 568-571.	1.7	25
94	Risk of second cancers in chronic myeloproliferative neoplasms. <i>Blood</i> , 2012, 119, 3861-3862.	0.6	14
95	Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. <i>Blood</i> , 2012, 120, 1327-1333.	0.6	99
96	Distinct Signal Transduction Abnormalities and Erythropoietin Response in Bone Marrow Hematopoietic Cell Subpopulations of Myelodysplastic Syndrome Patients. <i>Clinical Cancer Research</i> , 2012, 18, 3079-3089.	3.2	29
97	Romiplostim overcomes refractory secondary immune thrombocytopenia in a patient affected by serous ovarian carcinoma. <i>International Cancer Conference Journal</i> , 2012, 1, 239-242.	0.2	0
98	Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 617-626.	2.0	75
99	Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells. <i>Leukemia Research</i> , 2012, 36, 1290-1295.	0.4	14
100	Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients. <i>Annals of Hematology</i> , 2012, 91, 1013-1022.	0.8	36
101	Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. <i>Multiple Sclerosis Journal</i> , 2012, 18, 835-842.	1.4	115
102	Hydroxyurea-related toxicity in 3,411 patients with Ph <sup>-</sup> negative MPN. <i>American Journal of Hematology</i> , 2012, 87, 552-554.	2.0	105
103	Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients. <i>American Journal of Hematology</i> , 2012, 87, 1047-1051.	2.0	26
104	Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: A GITMO study. <i>Annals of Hematology</i> , 2012, 91, 931-939.	0.8	74
105	Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: results of a Società Italiana Di Emaferesi e Manipolazione Cellulare (SIDEM) and Gruppo Italiano Trapianto Midollo Osseo (GITMO) consensus process. <i>Transfusion</i> , 2012, 52, 893-905.	0.8	48
106	Single dose palonosetron and dexamethasone in preventing nausea and vomiting induced by high emetogenic ABVD regimen in Hodgkin Lymphoma patients. <i>Leukemia Research</i> , 2012, 36, 182-185.	0.4	11
107	Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. <i>Leukemia Research</i> , 2012, 36, 607-618.	0.4	19
108	Acquired severe aplastic anemia after H1N1 influenza virus vaccination successfully treated with allogeneic bone marrow transplantation. <i>Annals of Hematology</i> , 2012, 91, 475-476.	0.8	13

#	ARTICLE	IF	CITATIONS
109	Molecular analysis of population structure and antibiotic resistance of Klebsiella isolates from a three-year surveillance program in Florence hospitals, Italy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 371-378.	1.3	10
110	Familial Hemophagocytic Lymphohistiocytosis May Present during Adulthood: Clinical and Genetic Features of a Small Series. <i>PLoS ONE</i> , 2012, 7, e44649.	1.1	77
111	The Role of Bortezomib, Thalidomide and Lenalidomide in the Management of Multiple Myeloma. <i>Pharmacoeconomics</i> , 2011, 29, 269-285.	1.7	14
112	Human mesenchymal stromal cells preserve their stem features better when cultured in the Dulbecco's modified Eagle medium. <i>Cytotherapy</i> , 2011, 13, 539-548.	0.3	14
113	The impact of histopathologic examination of graft-versus-host disease in the era of reduced-intensity conditioning regimen: a study from the Gruppo Italiano Trapianto di Midollo Osseo. <i>Human Pathology</i> , 2011, 42, 254-268.	1.1	17
114	Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic Syndromes. <i>PLoS ONE</i> , 2011, 6, e23109.	1.1	95
115	Dendritic cells with lymphocyte-stimulating activity differentiate from human CD133 positive precursors. <i>Blood</i> , 2011, 117, 3983-3995.	0.6	11
116	Overexpression of microRNA-16-2 contributes to the abnormal erythropoiesis in polycythemia vera. <i>Blood</i> , 2011, 117, 6923-6927.	0.6	26
117	Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. <i>Blood</i> , 2011, 118, 2069-2076.	0.6	144
118	EZH2 mutational status predicts poor survival in myelofibrosis. <i>Blood</i> , 2011, 118, 5227-5234.	0.6	242
119	Concomitant occurrence of BCR-ABL and JAK2V617F mutation. <i>Blood</i> , 2011, 118, 3445-3446.	0.6	32
120	Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid. <i>Leukemia Research</i> , 2011, 35, 921-931.	0.4	13
121	Impact of Dose-Dense Immunochemotherapy on Prognosis of Germinal Center and Non Germinal Center Origin of Diffuse Large B Cell Lymphoma. <i>Journal of Chemotherapy</i> , 2011, 23, 227-231.	0.7	1
122	Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up. <i>Journal of Clinical Oncology</i> , 2011, 29, 3016-3022.	0.8	171
123	Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2011, 96, 937-942.	1.7	62
124	The conundrum of HLA-DRB1*14:01/*14:54 and HLA-DRB3*02:01/*02:02 mismatches in unrelated hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2011, 46, 916-922.	1.3	25
125	Prognostic Impact of EZH2 and ASXL1 Mutation in Myelofibrosis. <i>Blood</i> , 2011, 118, 2811-2811.	0.6	4
126	Inhibitors of PI3K/Akt and/or mTOR Inhibit the Growth of Cells of Myeloproliferative Neoplasms and Synergize with JAK2 Inhibitor and Interferon,. <i>Blood</i> , 2011, 118, 3835-3835.	0.6	7



#	ARTICLE	IF	CITATIONS
127	Treatment with Ruxolitinib (INC018424) Induced Changes of MicroRNA Expression in Granulocytes of Patients with Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , 2011, 118, 3852-3852.	0.6	1
128	High-Dose Rituximab in the Conditioning Regimen Before Allogeneic Stem Cell Transplantation Reduces the Incidence of Acute Gvhd in B-Cell Lymphomas. <i>Blood</i> , 2011, 118, 4546-4546.	0.6	0
129	Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. <i>Haematologica</i> , 2010, 95, 476-484.	1.7	144
130	Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. <i>Haematologica</i> , 2010, 95, 833-836.	1.7	34
131	Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. <i>Blood</i> , 2010, 116, 3171-3179.	0.6	290
132	Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. <i>Haematologica</i> , 2010, 95, 1435-1438.	1.7	41
133	Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome. <i>Annals of Hematology</i> , 2010, 89, 745-746.	0.8	1
134	Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin) ± rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma. <i>Cancer</i> , 2010, 116, 4573-4579.	2.0	28
135	Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. <i>Leukemia</i> , 2010, 24, 1533-1537.	3.3	22
136	BU/melphalan and auto-SCT in AML patients in first CR: a Gruppo Italiano Trapianto di Midollo Osseo (GITMO) retrospective study. <i>Bone Marrow Transplantation</i> , 2010, 45, 640-646.	1.3	17
137	OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOLLOWING REDUCED-INTENSITY CONDITIONING REGIMEN IN PATIENTS WITH IDIOPATHIC MYELOFIBROSIS: THE G.I.T.M.O. EXPERIENCE AND REVIEW OF THE LITERATURE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2010, 2, e2010010.	0.5	7
138	Molecular Characterization of <i>Acinetobacter</i> Isolates Collected in Intensive Care Units of Six Hospitals in Florence, Italy, during a 3-Year Surveillance Program: a Population Structure Analysis. <i>Journal of Clinical Microbiology</i> , 2010, 48, 1297-1304.	1.8	17
139	Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. <i>Blood</i> , 2010, 116, 335-342.	0.6	112
140	High recovery of mesenchymal progenitor cells with non-density gradient separation of human bone marrow. <i>Cytotherapy</i> , 2010, 12, 579-586.	0.3	17
141	Safety of Bone Marrow Stem Cell Donation: A Review. <i>Transplantation Proceedings</i> , 2010, 42, 2192-2194.	0.3	46
142	Autologous Mesenchymal Stem Cells Foster Revascularization of Ischemic Limbs in Systemic Sclerosis. <i>Annals of Internal Medicine</i> , 2010, 153, 650.	2.0	100
143	IHP Interpretation Criteria of Interim-PET Scan Confirms Prognostic Impact In Early Stage Hodgkin Lymphoma Patients without Bulky Disease. <i>Blood</i> , 2010, 116, 3890-3890.	0.6	4
144	Hepcidin Levels and Their Determinants In Different Types of Myelodysplastic Syndromes. <i>Blood</i> , 2010, 116, 4250-4250.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. <i>Haematologica</i> , 2009, 94, 230-238.	1.7	161
146	Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2009, 94, 102-112.	1.7	23
147	Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosome-“Negative” Myeloproliferative Neoplasms. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2068-2073.	1.1	100
148	JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis. <i>Haematologica</i> , 2009, 94, 144-146.	1.7	35
149	Molecular Surveillance and Population Structure Analysis of Methicillin-Susceptible and Methicillin-Resistant <i>Staphylococcus aureus</i> in High-Risk Wards. <i>Journal of Clinical Microbiology</i> , 2009, 47, 3246-3254.	1.8	3
150	Autologous stem cell transplantation improves microcirculation in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 94-98.	0.5	88
151	Prophylaxis and Treatment of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: Results of a Consensus Process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Clinical Infectious Diseases</i> , 2009, 49, 1226-1236.	2.9	51
152	Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: The crucial role of PTEN. <i>Experimental Hematology</i> , 2009, 37, 1176-1185.e21.	0.2	17
153	C003 Proliferative and apoptotic signalling in bone marrow cell subpopulations of myelodysplastic syndromes patients using flow-cytometry technique. <i>Leukemia Research</i> , 2009, 33, S32.	0.4	0
154	P117 Monocentric evaluation of response and tolerability of subcutaneous azacitidine in elderly MDS patients with comorbidities. <i>Leukemia Research</i> , 2009, 33, S127-S128.	0.4	0
155	Molecular epidemiological investigation of an outbreak of <i>Pseudomonas aeruginosa</i> infection in an SCT unit. <i>Bone Marrow Transplantation</i> , 2009, 43, 335-338.	1.3	26
156	HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry. <i>Bone Marrow Transplantation</i> , 2009, 44, 571-577.	1.3	48
157	Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). <i>Blood</i> , 2009, 113, 4153-4162.	0.6	387
158	Increase in FOXP3+ Regulatory T Cells in GVHD Skin Biopsies Is Associated with Lower Disease Severity and Treatment Response. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 938-947.	2.0	43
159	JAK2V617F mutation screening in patients with retinal vein thrombosis or recurrent fetal loss. <i>Thrombosis Research</i> , 2009, 124, 377-378.	0.8	1
160	Atypical Acute Leukemia Early After Liver Transplantation. <i>Transplantation Proceedings</i> , 2009, 41, 3945-3946.	0.3	3
161	Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. <i>Blood</i> , 2009, 114, 1477-1483.	0.6	196
162	Treatment options for essential thrombocythemia and polycythemia vera. <i>Expert Review of Hematology</i> , 2009, 2, 41-55.	1.0	6

#	ARTICLE	IF	CITATIONS
163	Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. <i>Blood</i> , 2009, 114, 1437-1444.	0.6	131
164	The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. <i>Haematologica</i> , 2009, 94, 1537-1545.	1.7	58
165	The mTOR Inhibitor, RAD001, Inhibits the Growth of Cells From Patients with Myeloproliferative Neoplasms.. <i>Blood</i> , 2009, 114, 2914-2914.	0.6	8
166	Imatinib as Salvage Therapy for Patients with Refractory cGVHD: the Interim Analysis of the Prospective GITMO* Multicenter Study*Gruppo Italiano Trapianto Di Midollo Osseo.. <i>Blood</i> , 2009, 114, 3558-3558.	0.6	1
167	Response Assessment After Induction Therapy in Diffuse Large B Cell Lymphoma (DLBCL): Role of Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) in Comparison with Computed Tomography (CT).. <i>Blood</i> , 2009, 114, 4995-4995.	0.6	1
168	The Association of a Salvage Treatment Containing Novel Agents Followed by Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning Regimen Improves Overall Survival and Time-to-Progression in Multiple Myeloma Patients Relapsing After Autologous Stem Cell Transplantation: A Multicentric Retrospective Study Based On Donor Availability.. <i>Blood</i> , 2009, 114, 4320-4320.	0.6	1
169	Treatment of Experimental Injury of Anal Sphincters with Primary Surgical Repair and Injection of Bone Marrow-Derived Mesenchymal Stem Cells. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 411-420.	0.7	86
170	Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. <i>Archives of Dermatological Research</i> , 2008, 300, 115-124.	1.1	91
171	Mesenchymal stem cells from JAK2V617F mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele. <i>Leukemia Research</i> , 2008, 32, 516-517.	0.4	17
172	Hypermethylation of <i>CXCR4</i> Promoter in CD34+ Cells from Patients with Primary Myelofibrosis. <i>Stem Cells</i> , 2008, 26, 1920-1930.	1.4	91
173	Immunohistochemical and FISH analyses identify synovitis associated with chronic GVHD after allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2008, 42, 289-291.	1.3	3
174	Human herpesvirus 6-associated limbic encephalitis in adult recipients of unrelated umbilical cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2008, 42, 693-695.	1.3	10
175	Stem cell transplantation for primary immunodeficiencies. <i>Bone Marrow Transplantation</i> , 2008, 41, S83-S86.	1.3	11
176	No role for CXCL12 G801A polymorphism in the development of extramedullary disease in acute myeloid leukemia. <i>Leukemia</i> , 2008, 22, 669-671.	3.3	7
177	Pulmonary mucormycosis with cervical lymph node involvement in a patient with acute myeloid leukaemia: a case report. <i>Mycoses</i> , 2008, 51, 354-356.	1.8	3
178	Cord blood banking. <i>Vox Sanguinis</i> , 2008, 95, 335-348.	0.7	35
179	The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. <i>British Journal of Haematology</i> , 2008, 141, 814-819.	1.2	40
180	PET positivity with bone marrow biopsy revealing sarcoidosis in a patient in whom bone marrow metastases had been suspected. <i>British Journal of Haematology</i> , 2008, 143, 306-306.	1.2	14

#	ARTICLE	IF	CITATIONS
181	A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. <i>BMC Cancer</i> , 2008, 8, 195.	1.1	46
182	Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implication for assessment of disease activity and treatment. <i>Journal of Neuroimmunology</i> , 2008, 199, 142-150.	1.1	71
183	Development of human striatal anlagen after transplantation in a patient with Huntington's disease. <i>Experimental Neurology</i> , 2008, 213, 241-244.	2.0	38
184	Peripheral blood blast clearance during induction therapy in acute myeloid leukemia. <i>Blood</i> , 2008, 111, 1746-1747.	0.6	25
185	A Sensitive Detection Method for MPLW515L or MPLW515K Mutation in Chronic Myeloproliferative Disorders with Locked Nucleic Acid-Modified Probes and Real-Time Polymerase Chain Reaction. <i>Journal of Molecular Diagnostics</i> , 2008, 10, 435-441.	1.2	47
186	Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. <i>Haematologica</i> , 2008, 93, 41-48.	1.7	146
187	Characteristics and clinical correlates of MPL 515W&gt;L/K mutation in essential thrombocythemia. <i>Blood</i> , 2008, 112, 844-847.	0.6	216
188	WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Blood</i> , 2008, 112, 895-902.	0.6	192
189	Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Haematologica</i> , 2008, 93, 1514-1522.	1.7	121
190	Haematopoietic stem cell transplantation for autoimmune disorders. <i>Current Opinion in Hematology</i> , 2008, 15, 594-600.	1.2	16
191	Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two cases. <i>Multiple Sclerosis Journal</i> , 2007, 13, 676-678.	1.4	24
192	B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. <i>Haematologica</i> , 2007, 92, 258-259.	1.7	26
193	Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. <i>Blood</i> , 2007, 110, 840-846.	0.6	419
194	Polycythemia vera following autologous transplantation for AML: insights on the kinetics of JAK2V617F clonal dominance. <i>Blood</i> , 2007, 110, 4620-4621.	0.6	11
195	Insights into JAK2-V617F mutation in CML. <i>Lancet Oncology</i> , The, 2007, 8, 864-866.	5.1	50
196	Comparative Proteomic Analysis of Chronic Myelogenous Leukemia Cells: Inside the Mechanism of Imatinib Resistance. <i>Journal of Proteome Research</i> , 2007, 6, 367-375.	1.8	28
197	ATP Modulates Cell Proliferation and Elicits Two Different Electrophysiological Responses in Human Mesenchymal Stem Cells. <i>Stem Cells</i> , 2007, 25, 1840-1849.	1.4	76
198	Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. <i>Digestive and Liver Disease</i> , 2007, 39, S129-S133.	0.4	18

#	ARTICLE	IF	CITATIONS
199	Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. <i>Hematological Oncology</i> , 2007, 25, 198-203.	0.8	57
200	Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia. <i>Cancer</i> , 2007, 109, 343-343.	2.0	3
201	Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group. <i>Bone Marrow Transplantation</i> , 2007, 39, 347-352.	1.3	50
202	Treatment of refractory chronic GVHD with rituximab: a GITMO study. <i>Bone Marrow Transplantation</i> , 2007, 40, 273-277.	1.3	152
203	Event-free survival and cost-effectiveness in adult acute lymphoblastic leukaemia in first remission treated with allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2007, 40, 643-649.	1.3	23
204	Significance of CTLA-4 and CD14 genetic polymorphisms in clinical outcome after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2007, 40, 1001-1002.	1.3	22
205	Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. <i>Leukemia</i> , 2007, 21, 1952-1959.	3.3	328
206	Anaemia characterises patients with myelofibrosis harbouring MplW515L/Kmutation. <i>British Journal of Haematology</i> , 2007, 137, 244-247.	1.2	153
207	Molecular cytogenetic findings in a four-way t(1;12;5;12)(p36;p13;q33;q24) underlying the ETV6-PDGFRB fusion gene in chronic myelomonocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2007, 176, 67-71.	1.0	12
208	MicroRNA expression profile in granulocytes from primary myelofibrosis patients. <i>Experimental Hematology</i> , 2007, 35, 1708.e1-1708.e12.	0.2	71
209	Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma. <i>European Journal of Haematology</i> , 2007, 78, 330-337.	1.1	25
210	Molecular Profiling of CD34+Cells in Idiopathic Myelofibrosis Identifies a Set of Disease-Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1). <i>Stem Cells</i> , 2007, 25, 165-173.	1.4	111
211	Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomas. <i>Annals of Hematology</i> , 2007, 86, 565-568.	0.8	46
212	Positron emission tomography in the staging of patients with Hodgkin's lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. <i>Annals of Hematology</i> , 2007, 86, 897-903.	0.8	98
213	Use of CFDA-SE for evaluating the in vitro proliferation pattern of human mesenchymal stem cells. <i>Cytotherapy</i> , 2006, 8, 243-253.	0.3	46
214	<i>Pseudomonas aeruginosa</i> Sepsis in Stem Cell Transplantation Patients. <i>Infection Control and Hospital Epidemiology</i> , 2006, 27, 767-770.	1.0	4
215	Thymoglobulin Prevents Chronic Graft-versus-Host Disease, Chronic Lung Dysfunction, and Late Transplant-Related Mortality: Long-Term Follow-Up of a Randomized Trial in Patients Undergoing Unrelated Donor Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 560-565.	2.0	326
216	Inconsistencies in the association between the JAK2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases. <i>British Journal of Haematology</i> , 2006, 132, 652-654.	1.2	11

#	ARTICLE	IF	CITATIONS
217	Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study. <i>British Journal of Haematology</i> , 2006, 134, 54-57.	1.2	50
218	The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients. <i>Leukemia</i> , 2006, 20, 2074-2076.	3.3	51
219	Percutaneous vertebroplasty and kyphoplasty in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2006, 76, 180-181.	1.1	32
220	Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2006, 47, 167-169.	0.6	33
221	Low dose velcade, thalidomide and dexamethasone (LD-VTD): An effective regimen for relapsed and refractory multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2006, 47, 171-173.	0.6	38
222	Dose-Dense CHOP plus Rituximab (R-CHOP14) for the Treatment of Elderly Patients with High-Risk Diffuse Large B Cell Lymphoma: A Pilot Study. <i>Acta Haematologica</i> , 2006, 115, 22-27.	0.7	14
223	Influence of the Jak2V617F Mutational Load at Diagnosis on Major Clinical Aspects in Patients with Polycythemia Vera.. <i>Blood</i> , 2006, 108, 5-5.	0.6	14
224	First Line Treatment with Rituximab and Chlorambucil in the Treatment of Ocular Adnexal Lymphomas.. <i>Blood</i> , 2006, 108, 4712-4712.	0.6	0
225	Liposomal Doxorubicin in the Treatment of Elderly, Cardiopatic, or Pretreated Patients with Aggressive Lymphomas: Comparison with an Historical Series.. <i>Blood</i> , 2006, 108, 4685-4685.	0.6	0
226	The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. <i>Haematologica</i> , 2006, 91, 475-81.	1.7	213
227	Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. <i>Blood</i> , 2005, 105, 2601-2607.	0.6	147
228	Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. <i>British Journal of Haematology</i> , 2005, 128, 738-738.	1.2	89
229	Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease. <i>British Journal of Haematology</i> , 2005, 130, 271-275.	1.2	63
230	<i>Candida krusei</i> fungemia in an unrelated allogeneic hematopoietic stem cell transplant patient successfully treated with Caspofungin. <i>Bone Marrow Transplantation</i> , 2005, 35, 1215-1216.	1.3	4
231	Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. <i>Leukemia</i> , 2005, 19, 1847-1849.	3.3	236
232	Nephrotic Syndrome and Renal Failure After Allogeneic Stem Cell Transplantation: Novel Molecular Diagnostic Tools for a Challenging Differential Diagnosis. <i>American Journal of Kidney Diseases</i> , 2005, 46, 550-556.	2.1	35
233	Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma. <i>Cancer</i> , 2005, 103, 970-977.	2.0	8
234	Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials. <i>Annals of Oncology</i> , 2005, 16, 228-233.	0.6	24

#	ARTICLE	IF	CITATIONS
235	Pulmonary hypertension related to thalidomide therapy in refractory multiple myeloma. <i>Annals of Oncology</i> , 2005, 16, 1849-1850.	0.6	21
236	Abnormalities of GATA-1 in Megakaryocytes from Patients with Idiopathic Myelofibrosis. <i>American Journal of Pathology</i> , 2005, 167, 849-858.	1.9	62
237	Allogeneic Stem Cell Transplantation. <i>Transplantation Proceedings</i> , 2005, 37, 2667-2669.	0.3	24
238	18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results. <i>Oncology Reports</i> , 2005, 14, 1209-14.	1.2	28
239	Internal Tandem Duplications of Flt3Gene (Flt3/ITD) Predicts a Poor Post-Remission Outcome in Adult Patients with Acute Non-Promyelocytic Leukemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 73-78.	0.6	20
240	Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia. <i>New England Journal of Medicine</i> , 2004, 351, 2276-2285.	13.9	1,058
241	PRV-1 , erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia. <i>British Journal of Haematology</i> , 2004, 127, 214-219.	1.2	21
242	Front-Line Treatment of Acute Promyelocytic Leukemia with AIDA Induction Followed by Risk-Adapted Consolidation: Results of the AIDA-2000 Trial of the Italian GIMEMA Group.. <i>Blood</i> , 2004, 104, 392-392.	0.6	30
243	Treatment of large cell lymphoma in elderly patients with a mitoxantrone, cyclophosphamide, etoposide, and prednisone regimen. <i>Cancer</i> , 2003, 97, 97-104.	2.0	11
244	Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2003, 31, 481-486.	1.3	247
245	High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors. <i>Bone Marrow Transplantation</i> , 2003, 31, 767-773.	1.3	15
246	Impact of marrow unrelated donor search duration on outcome of children with acute lymphoblastic leukemia in second remission. <i>Bone Marrow Transplantation</i> , 2003, 32, 325-331.	1.3	26
247	PET Scan Evaluation of Thymic Mass After Autologous Peripheral Blood Stem-cell Transplantation in an Adult with Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, 2015-2018.	0.6	13
248	Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). <i>British Journal of Haematology</i> , 2002, 118, 1112-1119.	1.2	97
249	Second Allogeneic Bone Marrow Transplantation in Acute Leukemia: Results of a Survey by the European Cooperative Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2001, 19, 3675-3684.	0.8	173
250	Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). <i>Blood</i> , 2001, 98, 2942-2947.	0.6	487
251	Selective ex vivo expansion of cytomegalovirus-specific CD4+ and CD8+ T lymphocytes using dendritic cells pulsed with a human leucocyte antigen A*0201-restricted peptide. <i>British Journal of Haematology</i> , 2001, 113, 479-482.	1.2	21
252	Unrelated donor marrow transplantation: an update of the experience of the Italian Bone Marrow Group (GITMO). <i>Haematologica</i> , 2001, 86, 451-6.	1.7	16

#	ARTICLE	IF	CITATIONS
253	No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. <i>British Journal of Haematology</i> , 2000, 110, 308-314.	1.2	64
254	Unrelated donor marrow transplantation: an update of the experience of the Italian Bone Marrow Transplant Group (GITMO). <i>Haematologica</i> , 2000, 85, 30-6.	1.7	4
255	An Open Evaluation of Triple Antibiotic Therapy Including Vancomycin for Febrile Bone Marrow Transplant Recipients with Severe Neutropenia. <i>Journal of Chemotherapy</i> , 1999, 11, 287-292.	0.7	2
256	Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia. <i>Bone Marrow Transplantation</i> , 1999, 23, 489-495.	1.3	22
257	Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1999, 24, 47-51.	1.3	84
258	Human polyomavirus BK (BKV) load and haemorrhagic cystitis in bone marrow transplantation patients. <i>Journal of Clinical Virology</i> , 1999, 14, 79-86.	1.6	136
259	Fatal herpesvirus 6 encephalitis after unrelated bone marrow transplant. <i>Bone Marrow Transplantation</i> , 1998, 22, 285-288.	1.3	66
260	Evaluation of breast tumour cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNA. <i>British Journal of Haematology</i> , 1998, 103, 610-617.	1.2	54
261	Human parvovirus B19 infection in bone marrow transplantation patients. <i>American Journal of Hematology</i> , 1993, 44, 207-209.	2.0	59
262	Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: a randomized trial from the EBMT SAA working party. <i>British Journal of Haematology</i> , 1993, 83, 145-151.	1.2	107
263	Antiemetic Prophylaxis in Patients Undergoing Bone Marrow Transplantation: The Role of Ondansetron. <i>Leukemia and Lymphoma</i> , 1992, 7, 90-91.	0.6	0
264	Recombinant Human Erythropoietin: Clinical Experience in Bone Marrow Transplantation. <i>Leukemia and Lymphoma</i> , 1992, 7, 97-98.	0.6	1
265	Aztreonam versus Colistin-Neomycin for Selective Decontamination of the Digestive Tract in Patients Undergoing Bone Marrow Transplantation: a Randomized Study. <i>Journal of Chemotherapy</i> , 1992, 4, 30-34.	0.7	2
266	PKRD: a pharmacokinetic program for least-squares and bayesian analysis of repeated-dose pharmacokinetic curves. <i>Computer Methods and Programs in Biomedicine</i> , 1992, 38, 27-35.	2.6	6
267	Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study.. <i>Journal of Clinical Oncology</i> , 1991, 9, 432-437.	0.8	97
268	Impaired erythropoietin production in mice treated with cyclosporin A. <i>Blood</i> , 1991, 78, 1615-1618.	0.6	23
269	Impaired erythropoietin production in mice treated with cyclosporin A. <i>Blood</i> , 1991, 78, 1615-1618.	0.6	28
270	Inadequate erythropoietin production in allogeneic bone marrow transplant patients. <i>Haematologica</i> , 1991, 76, 280-4.	1.7	13



#	ARTICLE	IF	CITATIONS
271	In situ immunologic characterization of cutaneous involvement in Hodgkin's disease. <i>Cancer</i> , 1989, 63, 661-666.	2.0	13
272	Primary cutaneous follicular centre-cell lymphoma-a lymphoproliferative disease with favourable prognosis. <i>Clinical and Experimental Dermatology</i> , 1989, 14, 12-19.	0.6	93
273	Combined surgery and chemotherapy for the treatment of primary gastrointestinal intermediate- or high-grade non-Hodgkin's lymphomas. <i>British Journal of Cancer</i> , 1989, 60, 244-248.	2.9	50
274	Neutral maltase of human granulocytes: Localization on the extracytoplasmic side of the plasma membrane and some properties. <i>Biochemical Medicine and Metabolic Biology</i> , 1988, 40, 186-196.	0.7	1
275	PROGNOSTIC FACTORS IN HODGKIN'S DISEASE. <i>Lancet, The</i> , 1988, 331, 1117.	6.3	1
276	Hodgkin's Disease in the Elderly : A Retrospective Clinicopathologic Study of 61 Patients Aged over 60 Years. <i>Acta Haematologica</i> , 1987, 78, 163-170.	0.7	12
277	Treatment-related leukemia in Hodgkin's disease: A multi-institution study on 75 cases. <i>Hematological Oncology</i> , 1987, 5, 83-98.	0.8	26
278	Phenotypic and Ultrastructural Profile of M5 Leukemia Cells in Peripheral Blood and Skin Infiltrate. <i>Tumori</i> , 1986, 72, 63-69.	0.6	2
279	Acute leukaemia in patients treated for Hodgkin's disease. <i>British Journal of Haematology</i> , 1984, 58, 43-52.	1.2	55
280	Displacement of T Lymphocytes with the "Helper/Inducer" Phenotype from Peripheral Blood to Lymphoid Organs in Untreated Patients with Hodgkin's Disease. <i>Scandinavian Journal of Haematology</i> , 1983, 31, 305-314.	0.0	41
281	Primary Conjunctival Lymphoma: Response to Chemotherapy in 4 Cases. <i>Acta Haematologica</i> , 1982, 68, 161-162.	0.7	5
282	Second malignancy in patients treated for Hodgkin's disease. <i>Cancer</i> , 1980, 46, 1735-1740.	2.0	133